Retevmo Selpercatinib 80mg 120 Capsules

Retevmo (selpercatinib) is an oral kinase inhibitor that may be used to treat the following cancers caused by abnormal RET (rearranged during transfection) genes:

• locally advanced non-small cell lung cancer (NSCLC) or NSCLC that has spread in adults
• advanced or metastatic thyroid cancer in adults and children aged 2 years of age and older who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)
• advanced medullary thyroid cancer (MTC) or MTC that has spread and requires a medicine that treats the whole body (systemic therapy) in adults and children aged 2 years and older.